Orion Oyj

Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026

ORION CORPORATION
STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES
10 MARCH 2026 at 13.50 EET
        

Orion Corporation: Transfer of 172,778 own B shares on 10 March 2026

In accordance with a decision by the Board of Directors, Orion Corporation has on 10 March 2026 transferred altogether 172,778 Orion Corporation B shares held by the company as a share reward for earning period 2023–2025 and a reward for commitment part to the persons belonging to the Share-based Incentive Plan of Orion Group.

The transfer is based on the authorisation by the Annual General Meeting of 23 March 2022. After the share transfer, the total number of own B shares held by Orion Corporation is 268,166.

Orion Corporation has informed about the Share-based Incentive Plan in stock exchange release on 10 February 2022.

Orion Corporation

Contact person:
Julia Macharey, EVP, People & Culture and Communications
Mobile +358 50 486 8056
                                                 

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com

Orion Pharma is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals as well as active pharmaceutical ingredients, combining our trusted expertise with continuous innovation. We have an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by us are used to treat cancer, respiratory diseases and neurological diseases, among others. In 2025 our net sales amounted to EUR 1,890 million, and we employ about 4,000 professionals worldwide, dedicated to building well-being.